Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.

CDK4/6 inhibitor abemaciclib boosts PFS in first-line treatment of advanced breast cancer

Jackey Suen
13 Sep 2017
Dr Angelo Di Leo

Adding the CDK4/6 inhibitor abemaciclib to endocrine therapy improves progression-free survival (PFS) in first-line treatment of hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer, according to results of the phase III MONARCH 3 study presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. [ESMO 2017, abstract 236O_PR]

“This is the third study demonstrating that the combination of endocrine therapy with a CDK4/6 inhibitor is better than endocrine therapy alone, coming after the PALOMA-2 trial [with palbociclib] and MONALEESA-2 trial [with ribociclib],” said lead author Dr Angelo Di Leo of the Hospital of Prato, Istituto Toscano Tumori, Prato, Italy. [N Engl J Med 2016;375:1925-1936; N Engl J Med 2016;375:1738-1748]

“While most women in our study had substantial benefit from the addition of abemaciclib, we found that endocrine therapy alone may be sufficient in those with good prognosis,” he added.

In the MONARCH 3 study, 493 postmenopausal women with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer were randomized to receive letrozole 2.5 mg QD in combination with abemaciclib 150 mg BID or placebo.

“The study met its primary endpoint of investigator-assessed PFS after a median follow-up of 17.8 months. Median PFS was not reached in the abemaciclib arm vs 14.7 months in the placebo arm [hazard ratio (HR), 0.543; p=0.000021],” reported Di Leo. “The PFS benefit with abemaciclib was observed across all preplanned subgroups and confirmed by blinded independent central review [HR, 0.508; p=0.00102].”

Adding abemaciclib to letrozole also improved objective response rate (48.2 percent vs 34.5 percent for endocrine therapy alone; p=0.002). The overall survival (OS) data were immature for analysis.

Abemaciclib was generally well-tolerated in the study. Dose reduction (43.4 vs 6.2 percent) and treatment discontinuation (19.6 vs 2.5 percent) due to adverse events (AEs) were more frequently reported in patients receiving abemaciclib plus letrozole vs letrozole alone. Compared with letrozole alone, more patients receiving the combination had grade 3/4 diarrhoea, neutropenia, anaemia and leukopenia.

“In an exploratory PFS analysis of patients who had received prior endocrine therapy, the benefit of adding abemaciclib to letrozole was more pronounced in those who had a treatment-free interval [TFI] of <36 months [HR, 0.48] than those with a TFI of ≥36 months [HR, 0.83]. In addition, we found that the benefit of abemaciclib was less pronounced in patients with bone-only disease,” noted Di Leo. “These observations suggest that patients with indicators of poor prognosis had substantial benefit from the addition of abemaciclib. In contrast, endocrine therapy alone may be an appropriate initial therapy in patients with a long TFI or bone-only disease, which comprised one-third of the studied population in MONARCH 3.”

“The findings of this study are practice changing. The magnitude of PFS improvement with CDK4/6 inhibitors [palbociclib, ribociclib and abemaciclib] in combination with an aromatase inhibitor was observed across studies, suggesting that the benefit may be a class effect,” said discussant Professor Nicholas Turner of the Institute of Cancer Research, London, UK. “However, all three studies of CDK4/6 inhibitors in first-line treatment of locally advanced or metastatic breast cancer are substantially underpowered for OS.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.